^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SMT-NK
i
Other names: SMT-NK, SMT01
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
SMT Bio
Drug class:
NK cell stimulant
Related drugs:
almost2years
Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov)
P2b, N=128, Recruiting, SMT bio Co., Ltd.
New P2b trial • Combination therapy
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
|
PD-L1 expression • MSI-H/dMMR
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • SMT-NK
2years
Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer (clinicaltrials.gov)
P1/2; Recruiting --> Completed | Trial primary completion date: Feb 2021 --> Jun 2021
Combination therapy • Trial primary completion date • Trial completion
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
|
PD-L1 expression • MSI-H/dMMR
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • gemcitabine • SMT-NK
over4years
Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer (clinicaltrials.gov)
P1/2, N=40, Recruiting, SMT bio Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Jun 2019 --> Dec 2019
Clinical • Enrollment open • Trial initiation date • Combination therapy • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
|
PD-L1 expression • MSI-H/dMMR
|
Keytruda (pembrolizumab) • gemcitabine • SMT-NK
Share via
